Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.47
+2.8%		$2.77
$1.25
▼
$5.48
$147.50M2.9253,305 shs37,740 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.34
-0.7%		$5.98
$8.50
▼
$23.00
$39.61MN/A37,647 shs6,481 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.83
-1.4%		$0.92
$0.75
▼
$1.63
$167.88M1.11.23 million shs1.19 million shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.64
-2.5%		$0.84
$0.16
▼
$2.54
$155.69M0.7412.65 million shs2.92 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-0.69%-2.05%-58.19%-49.47%-58.79%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
+3.07%+3.57%-8.20%-13.78%-55.91%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-0.11%+7.38%-17.03%-22.41%-19.42%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-0.89%-3.70%+2.47%-61.65%-33.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.47
+2.8%		$2.77
$1.25
▼
$5.48
$147.50M2.9253,305 shs37,740 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.34
-0.7%		$5.98
$8.50
▼
$23.00
$39.61MN/A37,647 shs6,481 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.83
-1.4%		$0.92
$0.75
▼
$1.63
$167.88M1.11.23 million shs1.19 million shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.64
-2.5%		$0.84
$0.16
▼
$2.54
$155.69M0.7412.65 million shs2.92 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-0.69%-2.05%-58.19%-49.47%-58.79%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
+3.07%+3.57%-8.20%-13.78%-55.91%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-0.11%+7.38%-17.03%-22.41%-19.42%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-0.89%-3.70%+2.47%-61.65%-33.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
2.29
Hold$5.46272.95% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
2.60
Moderate Buy$4.19407.58% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.20
Hold$5.20713.77% Upside

Current Analyst Ratings Breakdown

Latest IZTC, LUCD, OTLK, and CLLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/16/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Underweight$9.00 ➝ $1.30
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$10.00 ➝ $8.00
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$4.00 ➝ $3.00
9/15/2026
Cellectis S.A. stock logo
CLLS
Cellectis
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
8/18/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/17/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$2.50
8/14/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
8/12/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/4/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/28/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$79.59M1.85N/AN/A$0.76 per share1.93
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$4.71M35.60N/AN/A($0.31) per share-2.66
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.35M115.23N/AN/A($0.60) per share-1.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$67.59M-$0.65N/AN/AN/A-102.34%-94.19%-21.34%11/13/2026 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$58.01M-$0.47N/AN/AN/A-959.76%N/A-119.57%11/11/2026 (Estimated)
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$0.77N/AN/AN/AN/AN/A-254.82%N/A

Latest IZTC, LUCD, OTLK, and CLLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.08-$0.09-$0.01-$0.15$0.97 million$0.01 million
8/12/2026Q2 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.0567-$0.06-$0.0033-$0.08$1.43 million$1.47 million
8/7/2026H1 2026
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.2630-$0.22+$0.0430-$0.22$11.05 million$6.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
1.61
1.37
1.37
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
1.33
1.31
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.81
0.63

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
6.90%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
229100.34 million83.87 millionOptionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
82203.24 million189.22 millionNo Data
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
17243.45 million239.07 millionOptionable

Recent News About These Companies

Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Update
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032622
FY2026 EPS Forecast for Oncobiologics Lifted by Analyst
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031626
Oncobiologics (NASDAQ:OTLK) and Synlogic (NASDAQ:SYBX) Critical Comparison
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031210
Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Up 65.4% in August
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-oncobiologics-inc-nasdaq-otlk-short-interest-up-654-in-august-2026-09-17/
Brokers Offer Predictions for Oncobiologics FY2026 Earnings
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-brokers-offer-predictions-for-oncobiologics-fy2026-earnings-2026-09-17/
Oncobiologics (NASDAQ:OTLK) Price Target Raised to $10.50 at Ascendiant Capital Markets
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-oncobiologics-nasdaq-otlk-price-target-raised-to-1050-at-ascendiant-capital-markets-2026-09-11/
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360236/0/en/outlook-therapeutics-fireside-chat-from-h-c-wainwright-conference-now-available-on-demand.html
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359613/0/en/outlook-therapeutics-ceo-bob-jahr-discusses-fda-approval-and-commercial-opportunity-for-lytenava-in-virtual-investor-ceo-connect-segment.html
Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Hold" from Analysts
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-oncobiologics-inc-nasdaq-otlk-receives-consensus-recommendation-of-hold-from-analysts-2026-09-09/
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352397/0/en/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-prepares-for-u-s-commercial-launch-of-lytenava.html
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352076/0/en/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-on-demand-conference.html
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975675/otlk-q3-earnings-call-maps-lytenava-u-s-launch-and-sales-ramp?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2975675
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
August 15, 2026  |  defenseworld.netD
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974790/outlook-therapeutics-inc-otlk-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974790
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972032/otlk-up-more-than-300-in-3-months-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2972032
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970019/outlook-therapeutics-inc-otlk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-2970019

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.47 +0.04 (+2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 0.00 (-0.34%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$6.34 -0.05 (-0.71%)
As of 09/24/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Lucid Diagnostics stock logo

Lucid Diagnostics NASDAQ:LUCD

$0.83 -0.01 (-1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 0.00 (0.00%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.64 -0.02 (-2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$0.65 +0.01 (+1.02%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas